Karras S, Anagnostis P, Krassas GE (2014) Vandetanib for the treatment of thyroid cancer: an

update. Expert Opin Drug Metab Toxicol 10(3):469–481

Kenney NJ, Bowman A, Korach KS, Barrett JC, Salomon DS (2003) Effect of exogenous

epidermal-like growth factors on mammary gland development and differentiation in the

estrogen receptor-alpha knockout (ERKO) mouse. Breast Cancer Res Treat 79(2):161–173

Kumar D, Mariappan G, Husain A, Monga J, Kumar S (2017) Design, synthesis and cytotoxic

evaluation of novel imidazolone fused quinazolinone derivatives. Arab J Chem 10(3):344–350

Kumar S, Sharma AK, Lalhlenmawia H, Kumar D (2021) Natural compounds targeting major

signaling pathways in lung cancer. In: Dua K, Löbenberg R, Malheiros Luzo ÂC, Shukla S,

Satija S (eds) Targeting cellular signalling pathways in lung diseases. Springer, Singapore.

https://doi.org/10.1007/978-981-33-6827-9_37

Li SN, Xu YY, Gao JY, Yin HR, Zhang SL, Li HQ (2015) Combination of 4-anilinoquinazoline

and rhodanine as novel epidermal growth factor receptor tyrosine kinase inhibitors. Bioorg Med

Chem 23(13):3221–3227

Liang D, Su Z, Tian W, Li J, Li Z, Wang C, Li D, Hou H (2020) Synthesis and screening of novel

anthraquinone–quinazoline multitarget hybrids as promising anticancer candidates. Future Med

Chem 12:111–126

Lin S, Li Y, Zheng Y, Luo L, Sun Q, Ge Z, Cheng T, Li R (2017) Design, synthesis and biological

evaluation of quinazoline–phosphoramidate mustard conjugates as anticancer drugs. Eur J Med

Chem 127:442–458

Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr

Relat Cancer 8(1):3–9

Molina-Pinelo S, Pastor MD, Paz-Ares L (2014) VeriStrat: a prognostic and/or predictive biomarker

for advanced lung cancer patients? Expert Rev Respir Med 8(1):1–4

Mowafy S, Galanis A, Doctor ZM, Paranal RM, Lasheen DS, Farag NA, Jänne PA, Abouzid KA

(2016) Toward discovery of mutant EGFR inhibitors; design, synthesis and in vitro biological

evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. Bioorg Med

Chem 24(16):3501–3512

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N,

Boggon TJ, Naoki K (2004) EGFR mutations in lung cancer: correlation with clinical response

to gefitinib therapy. Science 304(5676):1497–1500

Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V,

Munder M, Mateos MV, Mark TM (2016) Daratumumab, bortezomib, and dexamethasone for

multiple myeloma. N Engl J Med 375(8):754–766

Ravez S, Castillo-Aguilera O, Depreux P, Goossens L (2015) Quinazoline derivatives as anticancer

drugs: a patent review (2011–present). Expert Opin Ther Pat 25(7):789–804

Rawluk J, Waller CF (2018) Gefitinib. Recent Results Cancer Res 211:235–246

Shao J, Chen E, Shu K, Chen W, Zhang G, Yu Y (2016) 6-Oxooxazolidine–quinazolines as

noncovalent inhibitors with the potential to target mutant forms of EGFR. Bioorg Med Chem

24(16):3359–3370

Shirley M (2018) Dacomitinib: first global approval. Drugs 78(18):1947–1953

Song J, Jang S, Lee JW, Jung D, Lee S, Min KH (2019) Click chemistry for improvement in

selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.

Bioorg Med Chem Lett 29(3):477–480

Sternlicht MD, Sunnarborg SW (2008) The ADAM17–amphiregulin–EGFR axis in mammary

development and cancer. J Mammary Gland Biol Neoplasia 13(2):181–194

Stuckey DW, Hingtgen SD, Karakas N, Rich BE, Shah K (2015) Engineering toxin-resistant

therapeutic stem cells to treat brain tumors. Stem Cells 33(2):589–600

Tu Y, OuYang Y, Xu S, Zhu Y, Li G, Sun C, Zheng P, Zhu W (2016) Design, synthesis, and

docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.

Bioorg Med Chem 24(7):1495–1503

398

V. Panwar et al.